INTRODUCTION
============

Globally, breast cancer is a common cancer in women, with approximately 7% of breast cancers being caused by a hereditary predisposition \[[@B1]\]. Hereditary breast cancer is generally caused by mutations in the *BRCA1* or *BRCA2* gene \[[@B2],[@B3]\], with a high penetrance of *BRCA1* or *BRCA2* genetic mutations. In fact, it is estimated that women with either a *BRCA1* or a *BRCA2* genetic mutation have a 60% to 80% risk of developing breast cancer in their lifetime \[[@B4]\]. In a previous study, the estimated cumulative risk of breast cancer until the age of 70 years was 72.1% and 66.3% in *BRCA1* and *BRCA2* mutation carriers, respectively, in Korea \[[@B5]\].

Breast cancer patients can present with various clinical, pathological and molecular characteristics, some of which have prognostic significance. Several studies have shown that breast cancers involving *BRCA1* or *BRCA2* mutation are different from sporadic breast cancer cases. Several studies have demonstrated that *BRCA1* mutation carriers often do not express the estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) (termed triple-negative breast cancer) \[[@B6],[@B7],[@B8],[@B9]\]. In contrast, breast cancer cases with a *BRCA2* mutation share similar pathologic features to sporadic cancers \[[@B9],[@B10],[@B11]\].

Breast cancer phenotypes resulting from a patients\' genetic background are also likely to be racially influenced. Therefore, conducting race and country-specific investigations is important to understand the potential effects of race on breast cancer phenotypes. However, few such studies have been performed in Korea, and these studies were single center-based investigations with small cohort sizes \[[@B12]\].

To the best of our knowledge, this is the first study to use multicenter and registry data in Korea. The purpose of this study was to determine the clinical and pathological characteristics of breast cancer in Korean patients with positive for *BRCA1* or *BRCA2* mutations, compared to sporadic breast cancer from the Korean breast cancer registry.

METHODS
=======

Study population and data collection
------------------------------------

A total of 181 women were confirmed to be breast cancer patients with either *BRCA1* or *BRCA2* genetic mutations (termed the BRCA1 group or the BRCA2 group, respectively) by *BRCA* genetic testing. Until December 2010, patients were enrolled from eight hospitals (Asan Medical Center, Seoul National University Bundang Hospital, Seoul National University Hospital, Soonchunhyang University Hospital, Korea Cancer Center Hospital, Hallym University Sacred Heart Hospital, Samsung Medical Center, and Ajou University Hospital). All patients were previously enrolled in the Korean Hereditary Breast Cancer Study (KOHBRA) \[[@B13]\]. Patients undergoing neoadjuvant treatment were excluded. Clinical and pathological details of all breast cancer patients were obtained from the registry of the Korean Breast Cancer Society, which is representative of the general population of breast cancer patients in Korea (termed the registry group). This registry is a prospectively maintained database of the Korean Breast Cancer Society \[[@B14]\], and is estimated to include \>50% of all newly diagnosed breast cancer patients in Korea every year \[[@B15]\]. In the registry group, patients undergoing neoadjuvant treatment were also excluded. Up to December 2010, there were 55,387 breast cancer patients from the general population with available information in the registry database. The electronic medical records of patients in the BRCA1 and BRCA2 groups were reviewed and reconfirmed by each of the eight hospitals. Medical records of patients in the registry group (from the Korean breast cancer registry) were reviewed to obtain clinical and pathological information, including age at diagnosis, tumor size, axillary lymph node metastasis involvement, distant metastasis, Nottingham histological grade (modification of the Scarff-Bloom-Richardson grading system), modified Blacks nuclear grade, nodal status, as well as the expression status of the estrogen receptor, progesterone receptor, and HER2. In this study, hormone receptor and HER2 status were reviewed retrospectively by pathology reports at each hospital. Negative HER2 status was defined as \"negative\" or \"1+\" on immunohistochemistry in the medical records of each hospital and in the Korean breast cancer registry.

This study was approved by the Institutional Review Board (IRB) of Asan Medical Center (IRB number, 2010-0476) and the registry committee of the Korean Breast Cancer Society.

Statistical analysis
--------------------

An independent t-test was used to compare the mean age and mean tumor size across all groups. In addition, a chi-square test was used to determine differences between groups in the following characteristics: T stage, axillary lymph node metastasis, distant metastasis, histological grade, nuclear grade, nodal status, and the expression status of the estrogen receptor, progesterone receptor, and HER2. In all analyses, *p*-values less than 0.05 were considered statistically significant. All of the statistical analyses were performed using SPSS version 12.0 for Windows (SPSS Inc., Chicago, USA).

RESULTS
=======

Characteristics of patients in the BRCA1 and BRCA2 groups compared to those in the registry group
-------------------------------------------------------------------------------------------------

The median age at the time of diagnosis of patients in the BRCA1 group was 37 years (range, 19-62 years), which was younger than that of patients in the registry group (median age, 48 years; range, 12-96 years; *p*\<0.001). However, there was no difference in tumor size between the BRCA1 group and the registry group. Furthermore, patients in the BRCA1 group had tumors of higher histological (61.3% with histological grade 3, *p*\>0.001) and nuclear (37.5% with nuclear grade 3, *p*=0.004) grade than did general breast cancer patients of the registry group. The frequency of ductal carcinoma *in situ* in the BRCA1 group (3.7%) was lower than that in the registry group (10.3%). However, there was no significant difference in the proportion of patients with axillary node metastasis between the BRCA1 group and the registry group.

The BRCA1 group included more hormone receptor-negative cases and had a lower proportion of cases with HER2 overexpression, compared to the registry group. Triple-negative breast cancer cases were more prevalent than general breast cancer cases in the registry group (61.3% vs. 12.4%, *p*\<0.001).

Similar to the BRCA1 group, the BRCA2 group had a younger median age at diagnosis than the registry group (41 years vs. 48 years, *p*\<0.001). Despite no significant differences in tumor size, tumors of the BRCA2 group involved axillary nodes more often than did those of the registry group (45.5% vs. 33.5%, *p*=0.002). As observed in the BRCA1 group, there was also less HER2 overexpression in the BRCA2 group than in the registry group; however the distribution of HER2 expression grade differed between the BRCA2 group and the registry group. There were no other significant differences between the BRCA2 and the registry groups.

Triple-negative breast cancer presented more often in the BRCA1 group than in the BRCA2 and registry groups (BRCA1 group, 61.3%; BRCA2 group, 12.9%; and registry group, 12.4%) ([Table 1](#T1){ref-type="table"}).

Nodal status according to tumor size in the BRCA1, BRCA2, and registry groups
-----------------------------------------------------------------------------

The frequency of axillary node metastasis in breast cancer increases with increasing tumor size. However, unlike the registry group, there was no significant odds ratio of axillary lymph node involvement and increasing tumor size cancer in the BRCA1 and BRCA2 groups. In addition, BRCA1 group was even more likely to involve axillary lymph nodes in smaller-sized tumors ([Table 2](#T2){ref-type="table"}). A significant positive correlation was noted between tumor size and axillary nodal involvement in triple-negative and non-triple-negative patients of registry group, while no such correlation was seen in breast cancer cases of *BRCA* mutation carriers ([Table 3](#T3){ref-type="table"}).

DISCUSSION
==========

To the best of our knowledge, this is the first to utilize multicenter data and Korean breast cancer registry data to describe the clinical and pathological characteristics of *BRCA1* and *BRCA2* mutation-positive breast cancer cases in Korea. The features of *BRCA1*- and *BRCA2*-positive breast cancers were compared to those of the registry group. While cases of the registry group were not specifically identified as sporadic breast cancers, the registry group can be assumed to represent sporadic breast cancers considering the low *BRCA* mutation prevalence in Korea \[[@B3],[@B7]\].

Consistent with the findings of previous studies in other countries, this study showed differences in the characteristics of the BRCA1 and BRCA2 groups compared to the registry group, which represents sporadic breast cancer cases in Korea \[[@B9],[@B11],[@B16],[@B17]\].

Patients in the BRCA1 and BRCA2 groups were diagnosed with breast cancer at a younger age than those in the registry group, which confirms similar data from previous studies. However, *BRCA* mutation testing tends to be more easily performed in younger than in older breast cancer patients, which may present a selection bias in the present study as well as in previous studies in other countries \[[@B9]\]. The BRCA1 group presented with tumors that were higher histological and nuclear grades compared to the registry group. In contrast to the BRCA1 group, which had a low proportion of ductal carcinoma *in situ*, the T stage distribution of the BRCA2 group was not significantly different from that of the registry group. However, there was more frequent involvement of the axillary lymph node in patients of the BRCA2 group than in those of the registry group.

In breast cancer, the status of estrogen receptor, progesterone receptor, and HER2 expression has important clinical implications for disease treatment and prognosis \[[@B18]\]. Most studies showed a higher frequency of the triple-negative subtype of breast cancer in patients with a *BRCA1* mutation \[[@B9],[@B16],[@B17]\]. In this study, there was a significantly higher proportion of triple-negative breast cancer cases (no expression of the estrogen receptor, progesterone receptor, and no overexpression of HER2) in the BRCA1 group. In contrast, there was a similar proportion of triple-negative breast cancer cases in the BRCA2 group compared to the registry group. Interestingly, in a previous study, breast cancers involving *BRCA1* mutations were shown to cluster with the estrogen receptor-negative basal-like subgroup \[[@B19]\]. The underlying molecular basis of this phenotype specificity observed in patients with *BRCA1* mutations remains unknown. However, several investigators have attempted to identify the mechanism underlying estrogen receptor-negativity in breast cancers involving *BRCA1* mutations and have suggested that *BRCA1* may transcriptionally induce estrogen receptor α (ERα) mRNA expression \[[@B20]\]. Therefore, *BRCA1* mutations and the subsequent loss of heterozygosity in breast and ovary cancer patients may result in the inhibition of ERα expression \[[@B21]\]. However, the molecular basis of breast cancers involving *BRCA* mutations remains highly complex and dependent on potentially unknown functions of BRCA, such as possible effects of BRCA on the expression of progesterone receptor and HER2.

In general, the risk of axillary lymph node metastasis increases with increasing tumor size. However, a significant correlation between tumor size and axillary nodal involvement was not seen in patients of the BRCA1 and BRCA2 groups in this study. Considering the high proportion of triple-negative breast cancer cases in the BRCA1 group, we hypothesized that triple-negative breast cancers may be less susceptible to a correlation between tumor size and axillary node metastasis \[[@B22]\]. Therefore, we investigated the effect of triple-negative breast cancer status on the characteristics of tumors of the BRCA1 group. We first combined cases from all three groups (BRCA1, BRCA2, and registry groups) and then divided the cases into 2 groups (triple-negative breast cancers and non-triple-negative breast cancers). Consequently, in contrast to the findings from the BRCA1 and BRCA2 groups, in both triple-negative and non-triple-negative breast cancer groups, the odds ratio of axillary lymph node involvement increased according to tumor size. In particular, the BRCA1 group showed lower odds ratio of axillary lymph node involvement than did the registry group, suggesting that *BRCA1*-mutated breast cancers have other mechanisms for axillary node metastasis. Previous studies by other groups suggested that *BRCA1*-mutated breast cancers metastasize by early hematogenous dissemination regardless of tumor size, rather than by lymphatic spread \[[@B23]\].

In the present study, the BRCA1 group included a small proportion of patients with ductal carcinoma *in situ* tumors and high grade and hormone receptor-negative tumors. In addition, BRCA2 group tumors were more likely to involve the axillary lymph nodes. Therefore, breast cancers involving *BRCA* mutations showed several features associated with poor patient prognosis. However, previous studies did not show poor prognosis in *BRCA* mutation carriers. In an unselected cohort of triple-negative breast cancer cases, *BRCA* mutation carriers had a significantly better prognosis than patients without *BRCA* mutations \[[@B24],[@B25]\]. These results are not consistent with the poor prognostic features of the patients of the BRCA1 and BRCA2 groups in this study. Therefore, further research is required to confirm the prognostic significance of *BRCA* mutations in breast cancer.

In conclusion, *BRCA1* mutation-positive breast cancer cases have unique clinical and pathological features such as a younger patient age at diagnosis, lower proportion of ductal carcinoma *in situ*, higher tumor grade, and higher proportion of triple-negative breast cancer status. Breast cancers involving *BRCA2* mutations were also diagnosed at a younger age and more frequently involved axillary lymph nodes compared to the breast cancers from the registry group. Further studies are required to investigate the impact of *BRCA* mutations on the unique clinical and pathologic characteristics of breast cancer patients. In addition, the present results suggest that a varied approach tailored to individual patients, from screening and diagnosis to treatment and monitoring, is required to manage breast cancer patients with *BRCA* mutations in Korea.
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Characteristics of the BRCA1, BRCA2, and registry groups
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HER2=human epidermal growth factor receptor 2.

^\*^Median (range); ^†^Estrogen receptor (-) & progesterone receptor (-) & HER2 expression: 0 or 1+.
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Odds ratio of axillary node involvement according to tumor size in the BRCA1, BRCA2, and registry groups
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OR=odds ratio of positivity of axillary lymph node involvement.
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Tumor size and axillary lymph node involvement in the BRCA1 and BRCA2 groups compared to triple-negative and non-triple-negative breast cancer in the registry group
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OR=odds ratio of positivity of axillary lymph node involvement; Registry=patients of registry data; Non-TNT=non-triple-negative tumor; TNT=triple-negative tumor.
